title: Is it time to revisit standard post-remission therapy?
abstract: There are several strategies for improving post-remission therapy in acute myeloid leukemia (AML). One is a risk-adapted strategy for younger adults in which patients with non-favorable characteristics based on cytogenetics and genetics are allocated to allogeneic stem cell transplantation and others receive intensive high-dose ara-C-based therapies. Additional genetic data and/or minimal residual disease level may prove useful in post-remission therapeutic choice. Future approaches, badly needed in older AML patients, may include the addition of new agents to currently used therapies or maintenance with DNA methyltransferase inhibitors.
authors.affiliation: Harvard Medical School, Boston, MA, USA. rstone@partners.org
authors.forename: Richard M
authors.initials: RM
authors.lastname: Stone
mesh_terms: D000328:Adult; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000628:therapy*; D008297:Male; D012074:Remission Induction / Q000379:methods
chemical_list: D000964:Antimetabolites, Antineoplastic; D003561:Cytarabine